Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Hydrosat Unveils Osiris Constellation, The Future of Thermal Intelligence16.9.2026 08:00:00 CEST | Press release
Next-generation satellite constellation will combine high-resolution thermal imaging with broad-area coverage and daily revisit to support governments, businesses, and researchers worldwide. PARIS, FR / ACCESS Newswire / September 16, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced Osiris, its next-generation Earth observation constellation designed to deliver wide-area, high resolution intelligence for water and food security, critical infrastructure, and national security missions. At the core of each Osiris satellite is Hydrosat's next-generation thermal infrared payload, developed to collect high-resolution thermal data across exceptionally wide areas. Operating across three longwave infrared bands, the payload will capture imagery at 25-meter native resolution over 160-kilometer to 340-kilometer swath widths, addressing one of Earth observation's biggest challenges between spatial detail and collection scale. This
Innodata Appoints Admiral Michael S. Rogers, Former NSA Director and Commander of U.S. Cyber Command, to Its Board of Directors15.9.2026 16:35:00 CEST | Press release
One of the nation's most senior cyber and intelligence leaders will help guide Innodata's strategy as it accelerates Federal and cyber-related AI initiatives. NEW YORK, NY / ACCESS Newswire / September 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced the appointment of Admiral Michael S. Rogers, U.S. Navy (Retired) - the former Director of the National Security Agency (NSA) and Commander of U.S. Cyber Command - to its Board of Directors, effective immediately. One of the highest-ranking cyber and intelligence leaders ever to serve the United States, Admiral Rogers joins at a pivotal moment, as the AI industry, enterprises and the Federal government alike wrestle with how to make increasingly capable AI systems safe and secure - and as Innodata accelerates its Federal practice launched last Fall and launches new capabilities designed specifically to make AI systems demonstrably safe and secure. "There is no one better positioned to help guide this chapter of Innodata's growth than
MicroVision Showcases Expanding Perception Portfolio at IAA Transportation 202615.9.2026 15:20:00 CEST | Press release
New Perception Platform, next-generation MOVIA S, HALO, FMCW technology, and commercial vehicle concept demonstrate MicroVision's Lidar 2.0 strategy in action REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 15, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, is showcasing the expanding breadth of its sensing and perception portfolio this week at IAA Transportation 2026, demonstrating how lidar hardware, perception software, and open sensor integration can work together to address increasingly complex applications across transportation and autonomy. At the center of MicroVision's IAA presence is the newly introduced MicroVision Perception Platform™, a flexible, modular architecture designed to allow sensing and perception configurations to be tailored to the requirements of individual applications. Throughout IAA, MicroVision is bringing that strategy to life through a series of technology demonstrations and reference concepts spanning pa
U.S. Polo Assn. Taps David Swetman as Global Design Lead, Men's and Boys' as Brand Targets $4 Billion in Global Retail Sales15.9.2026 13:00:00 CEST | Press release
Former Abercrombie & Fitch Menswear Leader Joins U.S. Polo Assn. to Advance Global Growth and Elevate Brand Worldwide WEST PALM BEACH, FL / ACCESS Newswire / September 15, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), with a multi-billion-dollar global footprint and distribution in more than 190 countries through over 1,200 retail stores worldwide, today announced the appointment of David Swetman as Global Design Lead, Men's and Boys', further strengthening the sports brand's Global Product Leadership Team as U.S. Polo Assn. continues its worldwide expansion and evolution. U.S. Polo Assn. continues to expand as one of the world's largest and fastest-growing sports brands, serving consumers globally through its extensive retail, e-commerce, and licensing network. The appointment reflects U.S. Polo Assn.'s continued global growth and strategic investment in world-class talent as the brand expands its product innovation, strengthens its c
MTech Mobility Appoints Rodney Moore as General Manager, Europe, to Accelerate Regional Growth15.9.2026 12:00:00 CEST | Press release
Seasoned technology executive brings more than 30 years of enterprise IT leadership to Dublin as MTech Mobility deepens its European commitment following Aer Lingus implementation win DUBLIN, IRELAND / ACCESS Newswire / September 15, 2026 / MTech Mobility today announced the appointment of Rodney Moore as General Manager, Europe. Moore, based in Dublin, will lead MTech Mobility's European operations, expand the regional team, and serve as the primary point of contact for the company's growing base of European customers. "Our European customers face challenges that demand more than a remote relationship - they need a partner who is present, accountable, and embedded in their landscape. Rodney's appointment is a direct investment in that commitment. His track record across Ireland and the UK means he understands exactly what European enterprises face, and he has the depth of experience to help them solve it. We are not just expanding our footprint; we are building the kind of trusted par
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom